RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults

被引：131

作者：

Wen, Patrick Y. ^{[1
,2
]}

van den Bent, Martin ^{[3
]}

Youssef, Gilbert ^{[1
,2
]}

Cloughesy, Timothy F. ^{[4
]}

Ellingson, Benjamin M. ^{[5
]}

Weller, Michael ^{[6
,7
]}

Galanis, Evanthia ^{[8
]}

Barboriak, Daniel P. ^{[9
]}

de Groot, John ^{[10
]}

Gilbert, Mark R. ^{[11
]}

Huang, Raymond ^{[2
,12
]}

Lassman, Andrew B. ^{[13
,14
,15
]}

Mehta, Minesh ^{[16
]}

Molinaro, Annette M. ^{[17
]}

Preusser, Matthias ^{[18
]}

Rahman, Rifaquat ^{[19
]}

Shankar, Lalitha K. ^{[20
]}

Stupp, Roger ^{[21
,22
,23
,24
]}

Villanueva-Meyer, Javier E. ^{[25
,26
]}

Wick, Wolfgang ^{[27
,28
]}

Macdonald, David R. ^{[29
,30
]}

Reardon, David A. ^{[1
,2
]}

Vogelbaum, Michael A. ^{[31
,32
]}

Chang, Susan M. ^{[10
]}

机构：

[1] Dana Farber Canc Inst, Ctr Neurooncol, 450 Brookline Ave, Boston, MA 02215 USA

[2] Harvard Med Sch, Boston, MA USA

[3] Erasmus MC Canc Inst, Dept Neurooncol, Rotterdam, Netherlands

[4] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Tumor Program, Los Angeles, CA USA

[5] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, UCLA Brain Tumor Imaging Lab, Los Angeles, CA USA

[6] Univ Hosp Zurich, Dept Neurol, Zurich, Switzerland

[7] Univ Zurich, Zurich, Switzerland

[8] Mayo Clin, Dept Oncol, Rochester, MN USA

[9] Duke Univ, Med Ctr, Dept Radiol, Durham, NC USA

[10] Univ Calif San Francisco, Dept Neurosurg, Div Neurooncol, San Francisco, CA USA

[11] NCI, Neurooncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[12] Brigham & Womens Hosp, Dept Radiol, Div Neuroradiol, Boston, MA USA

[13] Columbia Univ, Vagelos Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Neurol,Div Neuroradiol, New York, NY USA

[14] Columbia Univ, Irving Inst Clin & Translat Res, Vagelos Coll Phys & Surg, New York, NY USA

[15] New York Presbyterian Hosp, New York, NY USA

[16] Miami Canc Inst, Miami, FL USA

[17] Univ Calif San Francisco, Dept Neurol Surg, Div Biomed Stat & Informat, San Francisco, CA USA

[18] Med Univ Vienna, Dept Med 1, Div Oncol, Vienna, Austria

[19] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA USA

[20] NCI, Clin Trials Branch, Canc Imaging Program, NIH, Bethesda, MD USA

[21] Northwestern Univ, Malnati Brain Tumor Inst, Lurie Comprehens Canc Ctr, Chicago, IL USA

[22] Northwestern Univ, Dept Neurol Surg, Chicago, IL USA

[23] Northwestern Univ, Dept Neurol, Chicago, IL USA

[24] Northwestern Univ, Div Hematol Oncol, Chicago, IL USA

[25] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA

[26] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA

[27] Heidelberg Univ Hosp, Dept Neurol, Heidelberg, Germany

[28] German Canc Res Ctr, ClinicalCooperat Unit Neurooncol, German Canc Consortium DKTK, Heidelberg, Germany

[29] Western Univ, Dept Clin Neurol Sci, London, ON, Canada

[30] Western Univ, Dept Oncol, London, ON, Canada

[31] H Lee Moffitt Canc Ctr & Res Inst, Dept Neurooncol, Tampa, FL USA

[32] H Lee Moffitt Canc Ctr & Res Inst, Dept Neurosurg, Tampa, FL USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 33期

关键词：

MALIGNANT GLIOMA; GLIOBLASTOMA; PSEUDOPROGRESSION; PROGRESSION; RECOMMENDATIONS; RECIST; PET;

D O I：

10.1200/JCO.23.01059

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSEThe Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time, some limitations of these criteria were identified, and challenges emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria.METHODSInformed by data from studies evaluating the different criteria, updates to the RANO criteria are proposed (RANO 2.0).RESULTSWe recommend a standard set of criteria for both high- and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the postradiotherapy magnetic resonance imaging (MRI), rather than the postsurgical MRI, will be used as the baseline for comparison with subsequent scans. Since the incidence of pseudoprogression is high in the 12 weeks after radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, are required to define tumor progression. However, confirmation scans are not mandatory after this period nor for the evaluation of treatment for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is highly recommended. The primary measurement remains the maximum cross-sectional area of tumor (two-dimensional) but volumetric measurements are an option. For IDH wild-type glioblastoma, the nonenhancing disease will no longer be evaluated except when assessing response to antiangiogenic agents. In IDH-mutated tumors with a significant nonenhancing component, clinical trials may require evaluating both the enhancing and nonenhancing tumor components for response assessment.CONCLUSIONThe revised RANO 2.0 criteria refine response assessment in gliomas.

引用

页码：5189 / +

页数：15

共 50 条

[41] Measuring clinical outcomes in neuro-oncology. A battery to evaluate low-grade gliomas (LGG)
Papagno, Costanza
Casarotti, Alessandra
Comi, Alessandro
Gallucci, Marcello
Riva, Marco
Bello, Lorenzo
JOURNAL OF NEURO-ONCOLOGY, 2012, 108 (02) : 269 - 275
[42] Intraoperative image-guided surgery in neuro-oncology with specific focus on high-grade gliomas
Mahboob, Syed O.
Eljamel, Muftah
FUTURE ONCOLOGY, 2017, 13 (26) : 2349 - 2361
[43] 111In-labelled bleomycin complex for the differentiation of high- and low-grade gliomas
Korppi-Tommola, T
Huhmar, H
Aronen, HJ
Penttilä, P
Hiltunen, J
Savolainen, S
Kallio, ME
Liewendahl, K
NUCLEAR MEDICINE COMMUNICATIONS, 1999, 20 (02) : 145 - 152
[44] Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
Erker, Craig
Tamrazi, Benita
Poussaint, Tina Y.
Mueller, Sabine
Mata-Mbemba, Daddy
Franceschi, Enrico
Brandes, Alba A.
Rao, Arvind
Haworth, Kellie B.
Wen, Patrick Y.
Goldman, Stewart
Vezina, Gilbert
MacDonald, Tobey J.
Dunkel, Ira J.
Morgan, Paul S.
Jaspan, Tim
Prados, Michael D.
Warren, Katherine E.
LANCET ONCOLOGY, 2020, 21 (06): : E317 - E329
[45] Pattern of FDG and MET Distribution in High- and Low-Grade Gliomas on PET Images
Takahashi, Miwako
Soma, Tsutomu
Mukasa, Akitake
Tanaka, Shota
Yanagisawa, Shunsuke
Momose, Toshimitsu
CLINICAL NUCLEAR MEDICINE, 2019, 44 (04) : 265 - 271
[46] Regarding "Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma" Response
Yeo, Kee Kiat
Mueller, Sabine
NEURO-ONCOLOGY PRACTICE, 2020, 7 (05) : 574 - 575
[47] Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group (Vol 21, pg e305, 2020)
Fangusaro, J.
Witt, O.
Driever, Hernaiz P.
LANCET ONCOLOGY, 2020, 21 (12): : E553 - E553
[48] CHEMOTHERAPY FOR IRRESECTABLE LOW GRADE GLIOMAS IN A UNIVERSITY-BASED COMBINED NEURO-ONCOLOGY SERVICE IN SOUTH AFRICA
Davidson, A.
Figaji, A.
Pillay, K.
Kilborn, T.
Padayachy, L.
Hendricks, M.
van Eyssen, A.
Parkes, J.
PEDIATRIC BLOOD & CANCER, 2014, 61 : S279 - S279
[49] Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma
Fatima Tensaouti
Jonathan Khalifa
Amélie Lusque
Benjamin Plas
Jean Albert Lotterie
Isabelle Berry
Anne Laprie
Elizabeth Cohen-Jonathan Moyal
Vincent Lubrano
Neuroradiology, 2017, 59 : 1013 - 1020
[50] Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma
Tensaouti, Fatima
Khalifa, Jonathan
Lusque, Amelie
Plas, Benjamin
Lotterie, Jean Albert
Berry, Isabelle
Laprie, Anne
Moyal, Elizabeth Cohen-Jonathan
Lubrano, Vincent
NEURORADIOLOGY, 2017, 59 (10) : 1013 - 1020

← 1 2 3 4 5 →